Revance Therapeutics, Inc.
$1.2M 21,446 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
New Wave Endo-Surgical Corp.
New Wave Endo-Surgical Corp. reported $1,165,200.00 across General Payments, Research, and Ownership to 1 physicians and teaching hospitals across 11 transactions.
- $1.2M Above-median payer
- All-tracks total
- 11 Below-median volume
- Transactions
- 1 Below-median reach
- Recipients
- −$616.32
- General Payments vs PY2023
New Wave Endo-Surgical Corp. reported $1,165,200.00 across all CMS Open Payments tracks (General + Research + Ownership) to 1 physicians and teaching hospitals in Program Year 2024 - ranking #586 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,200.00, averaging $1.2M per recipient.
How New Wave Endo-Surgical Corp.'s $1.2M all-tracks total breaks down
New Wave Endo-Surgical Corp.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
21/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer new-wave-endo-surgical-corp New Wave Endo-Surgical Corp.
$1.2M · #586/1,925 · 0.0% industry · PY2024
- TOT $1.2M
- RANK #586
- SHARE 0.0%
- TXN 11
- RCP 1
- CAT 1
- GEN $1.2K
- ΔGEN −$616.32
- TOP1 100.0%
- PY 2024
Volume peers
Nearest volume peer: Revance Therapeutics, Inc. ($1.2M)
New Wave Endo-Surgical Corp. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
New Wave Endo-Surgical Corp.'s CMS-reported General Payments decreased by $616.32 (−33.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NEW WAVE ENDO-SURGICAL CORP.PY2023: NEW WAVE ENDO-SURGICAL CORP.PY2024: New Wave Endo-Surgical Corp.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,816.32
- PY2024
- $1,200.00
What the Data Shows for New Wave Endo-Surgical Corp.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For New Wave Endo-Surgical Corp., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Grant" leads the 1-category general-payment breakdown below at $1.2K (100.0% of General Payments, 1 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 1 types of general payments, New Wave Endo-Surgical Corp.'s largest category was "Grant" at $1.2K - 100.0% of General Payments.
How New Wave Endo-Surgical Corp. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Grant | $1.2K | 1 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,200.00 (100.0%) of $1,200.00 in this company's General Payments records across 1 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for New Wave Endo-Surgical Corp.
The five named recipients with the highest reported General Payments from this company
- 1
Alexander Ramirez Valderrama
$1,200.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
New Wave Endo-Surgical Corp. ranks #586 of 1,925 by total payments (top 30% by spend) but is notably more concentrated than that alone would suggest -- #130 of 1,838 by HHI (top 7% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Surgical Information Sciences, Inc. : $22.2K total payments, HHI 10000
- Lumenis BE ANZ Pty Ltd : $1.9K total payments, HHI 10000
- SiteSaver Inc. : $4.3K total payments, HHI 10000
- Elekta Solutions AB : $2.4K total payments, HHI 10000
- Substrate HD : $72.2K total payments, HHI 10000
- TightLine Development, LLC : $750.0K total payments, HHI 10000
- New Wave Endo-Surgical Corp. (this company) : $1.2K total payments, HHI 10000
- Ottobock SE & Co. KGaA : $306.0K total payments, HHI 10000
- VoxNeuro USA Inc. : $2.0K total payments, HHI 10000
- Solco Biomedical Co., Ltd. : $50.0K total payments, HHI 10000
- PAVmed Inc. : $2.8K total payments, HHI 10000
- Advanced Instruments, LLC : $3.1K total payments, HHI 10000
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as New Wave Endo-Surgical Corp.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about New Wave Endo-Surgical Corp..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with New Wave Endo-Surgical Corp..
Showing 6 of 1,924 companies with CMS-reported payment data.
Occlutech US LLC
$1.2M 120 recipients
Compare payment profiles
Noah Medical Corporation
$1.2M 1,750 recipients
Compare payment profiles
Organ Recovery Systems, Inc.
$1.2M 84 recipients
Compare payment profiles
BTG International, Inc.
$1.2M 757 recipients
Compare payment profiles
DiaSorin Inc.
$1.2M 37 recipients
Compare payment profiles
Put this to use
New Wave Endo-Surgical Corp. ranks #586 of 1,925 by all-tracks total payments, led by "Grant".
- See where New Wave Endo-Surgical Corp. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Grant" spend across every manufacturer, not just New Wave Endo-Surgical Corp.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.